New hope for cancer patients with dangerous gene flaw: safer chemo combo tested
NCT ID NCT06245356
First seen Dec 12, 2025 · Last updated May 08, 2026 · Updated 18 times
Summary
This study tests a different chemotherapy drug (trifluridine/tipiracil) for people with metastatic colorectal or gastroesophageal cancer who have a genetic condition (DPD deficiency) that makes standard chemo very toxic. About 73 participants will receive this drug along with other targeted therapies. The main goal is to see if this approach causes fewer severe side effects like diarrhea, mouth sores, and dangerous drops in white blood cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CH de Saint-Malo
ACTIVE_NOT_RECRUITINGSt-Malo, 35403, France
-
CHU Amiens
NOT_YET_RECRUITINGAmiens, 80054, France
Contact
-
CHU Jean Minjoz
ACTIVE_NOT_RECRUITINGBesançon, 25000, France
-
CHU Saint-Etienne
ACTIVE_NOT_RECRUITINGSaint-Priest-en-Jarez, 42270, France
-
CHU de Poitiers
ACTIVE_NOT_RECRUITINGPoitiers, 86000, France
-
CHU de REIMS
ACTIVE_NOT_RECRUITINGReims, 51092, France
-
Centre Georges François Leclerc
WITHDRAWNDijon, 21079, France
-
Centre Hospitalier de Cholet
ACTIVE_NOT_RECRUITINGCholet, 49300, France
-
Hospices Civils de Lyon
ACTIVE_NOT_RECRUITINGPierre-Bénite, 69495, France
-
Hôpital Cochin
ACTIVE_NOT_RECRUITINGParis, 75014, France
-
Hôpital Nord Franche-Comté / Site du Mittan
ACTIVE_NOT_RECRUITINGTrévenans, 90400, France
-
Hôpital Privé Jean Mermoz
ACTIVE_NOT_RECRUITINGLyon, 69008, France
-
Hôpital Saint Antoine
RECRUITINGParis, 75012, France
Contact
-
Hôpital Saint Louis
ACTIVE_NOT_RECRUITINGParis, 75010, France
-
Hôpital des Diaconesses Croix Saint Simon
ACTIVE_NOT_RECRUITINGParis, 75960, France
-
Institut Godinot
RECRUITINGReims, 51100, France
Contact
-
Institut Régional du Cancer de Montpellier - ICM Val d'Aurelle
RECRUITINGMontpellier, 34298, France
Contact
-
Institut de Cancérologie de Lorraine
ACTIVE_NOT_RECRUITINGVandœuvre-lès-Nancy, 54519, France
-
Institut de Cancérologie de l'Ouest
NOT_YET_RECRUITINGAngers, 49055, France
Contact
-
Institut de Cancérologie de l'Ouest - Site René Gauducheau
WITHDRAWNSaint-Herblain, France
-
Institut du Cancer d'Avignon
ACTIVE_NOT_RECRUITINGAvignon, 84918, France
Conditions
Explore the condition pages connected to this study.